Atrial Fibrillation
Pipeline by Development Stage
Drug Modality Breakdown
Atrial Fibrillation is a ~$43.6B Part D market dominated by anticoagulants, mature and consolidating around a handful of blockbuster players.
Key Trends
- DOACs (FXa inhibitors) command 98% of spending; anticoagulation-first standard of care is locked in
- Patent cliff risk: ELIQUIS (apixaban) generic launches 2041; PRADAXA generic already eroded (post-LOE as of 2026)
- Older antiarrhythmics (digoxin, dofetilide, ibutilide) declining to negligible revenue; few new mechanisms in late-stage pipeline
Career Verdict
Strong career choice if you target commercial/medical affairs around market consolidation and generic defense; moderate if seeking early-stage innovation (pipeline is thin).
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 42% | PEAK | Stable | 5.3yr |
| 2 | XARELTO (rivaroxaban) | Johnson & Johnson | $6.3B | 14% | PEAK | Stable | |
| 3 | MULTAQ (dronedarone) | Sanofi | $409M | 1% | PEAK | Declining | 5.2yr |
Drug Class Breakdown
stable, high barrier to entry
stable, second-line preference
declining, niche use
declining post-LOE
near-obsolete
Career Outlook
StableAtrial Fibrillation is a mature, anticoagulation-dominated market with limited room for clinical innovation but strong commercial execution needs. Consolidation around ELIQUIS and XARELTO means career growth is tied to market access, managed care negotiation, and preparing for generic erosion post-2031. International expansion and real-world evidence generation remain active areas.
Breaking In
Target payer-facing or medical affairs roles at BMS or J&J to learn market dynamics and consolidation playbooks; AF is too mature for first-time product launches.
For Experienced Professionals
If you have competitive DOAC defense or managed care expertise, BMS and J&J need it now; if you prefer innovation, pivot to heart failure or arrhythmia device companies where unmet needs remain higher.
In-Demand Skills
Best For
Hiring Landscape
5,372 jobs across 10 companies, with Johnson & Johnson (1,798 jobs), Sanofi (1,121 jobs), and Bristol Myers Squibb (760 jobs) leading. Commercial roles dominate (911 jobs, $266K avg salary), followed by Manufacturing (516 jobs). Consolidation and patent cliff risk mean hiring is defensive (market maintenance) rather than growth-oriented.
By Department
Steady hiring in commercial and manufacturing reflects market maintenance; R&D roles are scarce and heavily concentrated in BMS and J&J.
On Market (6)
Approved therapies currently available
Competitive Landscape
93 companies ranked by most advanced pipeline stage
+63 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 37,238 patients across 50 trials
Metabolic Surgery for Atrial Fibrillation Elimination
Ondansetron for the Management of Atrial Fibrillation
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
Resolution of Thrombi in Left Atrial Appendage With Edoxaban
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Graz Study on the Risk of Atrial Fibrillation
Statin Therapy In Cardiac Surgery
DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial
Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation
Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)
Corticosteroid Pulse After Ablation
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
Reveal® XT Performance Trial (XPECT)
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
Avoid FFS - Use of the Atrial Pacemaker Lead 1699 With Very Short Tip Ring Spacing to Avoid Far Field Sensing
Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
Prevention of Atrial Fibrillation Following Esophagectomy
Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation
Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery
Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
Related Jobs in Cardiovascular
Therapy Development Manager (Tampa, FL)
Director, Patient Marketing
Chemistry Manufacturing & Controls (CMC) Manager
Senior Therapeutic Area Specialist, Cardiovascular Specialty - Wilmington, DE
Associate Director, US Medical Learning, Cardiovascular (CV)
Senior Therapeutic Area Specialist, Cardiovascular Community - Upper Manhattan E
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.